Get started
Prothena Corporation plcProthena Corporation plcProthena Corporation plc

Prothena Corporation plc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

PRTA trade ideas

PRTA - Short Idea Hi everyone. As we have seen the markets have been extremely red for the past few days. Even with that, this particular stock, PRTA, soared on Alzheimer related news. These news were not particular to the company; however, the stock did go up around 90%. We currently have a huge fap to fill. I don't mean to sound greedy, but my price target on this play is around 35$-40$. I plan to start a 5 figure position on this play. Stock has shown overbought signs as we can see on the RSI, as it broke above that 70 key level. Once again, this stock will take its time to come back down as it has a high percentage of institutional ownership, around 95% to be exact. I like this play and therefore that is why I have decided to go on heavier than usual. Good luck to everyone.
NASDAQ:PRTAShort
by LukeCharts07
PRTA High Tight FlagHigh tight flag chart pattern forms when a stock rises over 90% (preferably 100%) or more in two months, then consolidates sideways for 15-25 days with a decline of no more than 25%. When there's a breakout of the sideways 'flag' on high volume , the powerful uptrend often resumes. The entry point is either as the stock breaks the high of the flag or breaks a downtrend line - but only ever on higher than average volume/ With a decline in the flag of 15%, would be looking to enter on a breakout of the high of the flag with higher than average volume.
NASDAQ:PRTA
by Andy-Brittain
Jefferies upgraded $PRTA to buy from neutral-100% upside1. Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock. Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the price target to $30 from $15, nearly double its previous close. Prothena’s pipeline has significantly expanded and improved. The company’s early-stage candidates for Alzheimer’s disease ‘should start to garner more attention,’ Yee argues, projecting the three mid-to-late-stage assets to yield ‘a significant upside.’ Add more than $300M in cash and the partnerships with Bristol Myers and Roche, the stock ‘is primed to move up 100% towards $30+,’ concluded the analyst. Out of Prothena's two candidates, PRX012 and multi-immunogen vaccine, targeting the Alzheimer’s disease, the former is on track for an IND filing in Q1 2022, the company disclosed in the recent R & D update. ------------------------------------------------------------------------------------------------------------------------------------------------- 2. BTIG Research upgraded $PRTA from neutral to buy with price target $29. seekingalpha.com
NASDAQ:PRTA
by AlenCiken
2